Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE

Amyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including...

Full description

Bibliographic Details
Main Authors: Alena V Savonenko, Guilian M Xu, Donald L Price, David R Borchelt, Alicja L Markowska
Format: Article
Language:English
Published: Elsevier 2003-04-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996102000128
id doaj-fd5a976eeb6d4d888e2ac2829326c61a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Alena V Savonenko
Guilian M Xu
Donald L Price
David R Borchelt
Alicja L Markowska
spellingShingle Alena V Savonenko
Guilian M Xu
Donald L Price
David R Borchelt
Alicja L Markowska
Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
Neurobiology of Disease
Place discrimination
Water maze
Longitudinal
Cross-sectional
Memory
β-Amyloid
author_facet Alena V Savonenko
Guilian M Xu
Donald L Price
David R Borchelt
Alicja L Markowska
author_sort Alena V Savonenko
title Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
title_short Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
title_full Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
title_fullStr Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
title_full_unstemmed Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE
title_sort normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant appswe
publisher Elsevier
series Neurobiology of Disease
issn 1095-953X
publishDate 2003-04-01
description Amyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including deposits of β-amyloid (Aβ), neuritic plaques, and glial responses. In studies of cognition in these animals, there have been several reports of memory disturbances well before the appearance of amyloid deposits. We have developed two distinct lines of transgenic mice (C3-3 and E1-2) that express the “Swedish” variant of APP (APPSWE) at levels that are approximately three-fold higher than endogenous mouse APP. Both lines have been backcrossed to C57BL/6J mice for 10 generations. Here, we use longitudinal and cross-sectional studies to evaluate the cognitive performance of our animals, where the concentration of Aβ1-42 in brain increases with aging from low levels (2–10 pmol/g) at 6–14 months of age to relatively high levels (60–100 pmol/g) at 24–26 months, when deposits of Aβ were beginning to form. When 12-month-old mice were tested in tasks that assess reference and working memory, transgenic mice from both lines could not be distinguished from nontransgenic littermates. Further study of 24- to 26-month-old transgenic mice (C3-3 line) found no evidence of memory impairment despite the presence of high levels of human Aβ (60–100 pmol/g). Thus, the expression of APPSWE at approximately three-fold over endogenous levels, which is sufficient to induce amyloid deposition at advanced ages, does not significantly erode cognitive performance in aged mice.
topic Place discrimination
Water maze
Longitudinal
Cross-sectional
Memory
β-Amyloid
url http://www.sciencedirect.com/science/article/pii/S0969996102000128
work_keys_str_mv AT alenavsavonenko normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe
AT guilianmxu normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe
AT donaldlprice normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe
AT davidrborchelt normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe
AT alicjalmarkowska normalcognitivebehaviorintwodistinctcongeniclinesoftransgenicmicehyperexpressingmutantappswe
_version_ 1724212194122399744
spelling doaj-fd5a976eeb6d4d888e2ac2829326c61a2021-03-20T04:47:36ZengElsevierNeurobiology of Disease1095-953X2003-04-01123194211Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWEAlena V Savonenko0Guilian M Xu1Donald L Price2David R Borchelt3Alicja L Markowska4Department of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USADepartment of Psychology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Department of Pathology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205, USAAmyloid deposition appears to be an early and crucial event in Alzheimer’s disease (AD). To generate animal models of AD, mice expressing full-length amyloid precursor protein (APP), with mutations linked to FAD, have been created. These animals exhibit abnormalities characteristic of AD, including deposits of β-amyloid (Aβ), neuritic plaques, and glial responses. In studies of cognition in these animals, there have been several reports of memory disturbances well before the appearance of amyloid deposits. We have developed two distinct lines of transgenic mice (C3-3 and E1-2) that express the “Swedish” variant of APP (APPSWE) at levels that are approximately three-fold higher than endogenous mouse APP. Both lines have been backcrossed to C57BL/6J mice for 10 generations. Here, we use longitudinal and cross-sectional studies to evaluate the cognitive performance of our animals, where the concentration of Aβ1-42 in brain increases with aging from low levels (2–10 pmol/g) at 6–14 months of age to relatively high levels (60–100 pmol/g) at 24–26 months, when deposits of Aβ were beginning to form. When 12-month-old mice were tested in tasks that assess reference and working memory, transgenic mice from both lines could not be distinguished from nontransgenic littermates. Further study of 24- to 26-month-old transgenic mice (C3-3 line) found no evidence of memory impairment despite the presence of high levels of human Aβ (60–100 pmol/g). Thus, the expression of APPSWE at approximately three-fold over endogenous levels, which is sufficient to induce amyloid deposition at advanced ages, does not significantly erode cognitive performance in aged mice.http://www.sciencedirect.com/science/article/pii/S0969996102000128Place discriminationWater mazeLongitudinalCross-sectionalMemoryβ-Amyloid